This research demonstrates that fucoidan-copper nanoparticles induce cuproptosis in liver cancer cells, suggesting a new cancer therapy approach.
Cuproptosis, a newly characterized form of regulated cell death initiated by copper binding to lipoylated components of the tricarboxylic acid cycle, presents a promising target for cancer therapy. Here, we reported the development of fucoidan-copper nanoparticles (Fu-Cu) that exploit this mechanism to selectively induce cytotoxicity in HuH-7 liver cancer cells. Fu-Cu was synthesized using fucoidan, a sulfated polysaccharide with inherent anticancer properties, as a natural nanocarrier for copper ions. Characterization confirmed successful copper incorporation and the formation of stable nanoparticles. Knockout of ferredoxin 1 in HuH-7 cells mitigated the cytotoxic effects of Fu-Cu, underscoring its critical role in copper-induced cell death. Furthermore, we investigated the toxicity and mechanistic effects of Fu-Cu in Caenorhabditis elegans. In vivo studies using a subcutaneous tumor model in BALB/c nude mice demonstrated that Fu-Cu effectively inhibited tumor growth. Notably, Fu-Cu treatment was associated with enhanced innate immune cell infiltration in the tumor microenvironment, including increased NK-cell and macrophage recruitment, along with elevated peripheral CD19⁺ B-cell frequencies. These findings highlight Fu-Cu as a novel therapeutic strategy for hepatocellular carcinoma, leveraging both cuproptosis induction and tumor immune microenvironment enhancement to suppress tumor progression.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: